echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Nanoencapsulated rituximab mediates excellent cellular immunity against metastatic B-cell lymphoma in a humanized mouse model with complement activity

    J Immunother Cancer: Nanoencapsulated rituximab mediates excellent cellular immunity against metastatic B-cell lymphoma in a humanized mouse model with complement activity

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Therapeutic monoclonal antibodies (mAbs), such as anti-CD20 rituximab (RTX) for non-Hodgkin's lymphoma (NHL) and trastuzumab/herceptin for breast cancer (anti-Her2) change the tradition The way of cancer treatment has revolutionized cancer treatment.


    Therapeutic monoclonal antibodies (mAbs), such as anti-CD20 rituximab (RTX) for non-Hodgkin's lymphoma (NHL) and trastuzumab/herceptin for breast cancer (anti-Her2) change the tradition The way of cancer treatment has revolutionized cancer treatment.


    In order to create a favorable system successfully implanted human cells, the lack of a common cytokine receptor γ chain (IL- 2Rγ) advanced immunodeficiency NOD.


    Lack of common cytokine receptor γ chain (IL- 2Rγ) advanced immunodeficiency NOD.


    In this study, a new strain of NSG established a humanized mouse model, i.


    -Hc1 Prkdc SCID -Hc1

    The results of the study are as expected.


    -Hc1 -Hc1

    In summary, NSG- Hc1 mice can be used as a viable model, which can be used to study the use of cancer-targeted anti-tumor therapies, and to understand the induction mechanism of anti-tumor cell immune responses.


    NSG- Hc1 mice can be used as a viable model, which can be used to study the use of cancer-targeted anti-tumor therapies, and to understand the induction mechanism of anti-tumor cell immune responses.
    -Hc1 WenJ ,WangL ,RenJ WenJ Wen WangL Wang RenJ Ren , et al.
    bmj.
    com/content/9/2/e001524" target="_blank" rel="noopener">Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
    Journal for ImmunoTherapy of Cancer  2021; 9: e001524.
      doi:  10.
    1136/jitc-2020-001524 doi: leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.